Clinical trials: Attention Deficit Disorder With Hyperactivity (ADHD)
Attention-Deficit/Hyperactivity Disorder (ADHD)
Evaluation of Immediate-Release Viloxazine in Adults With ADHD
This will be a randomized, double-blind, placebo-controlled, parallel group, safety and tolerability study in adults with ADHD. The target subjects are healthy male or female adults aged 18 to 64 years, inclusive, with a…
- Trial name
- NCT01107496
- Testing
- IR Viloxazine
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
ADHD
Genetic Modulation of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)
In this study the investigators will measure the functional brain activity of adult Attention Deficit Hyperactivity Disorder (ADHD) patients, genotyped according to the COMT genotype, during a Working Memory Paradigm, before and…
- Trial name
- BEAS (NCT01351272)
- Testing
- Methylphenidate, non-retard
- Where
- Germany
- Volunteers
- 41 people
- Sponsor
- Wuerzburg University Hospital
ADHD, Attention Deficit Hyperactivity Disorder
Brain Plasticity Underlying Acquisition of New Organizational Skills in Children
Organizational, time management and planning (OTMP) skills deficits are impairing features of developmental disorders, such as Attention Deficit Hyperactive Disorder (ADHD), which compromise school performance and family…
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, Neurodevelopmental Disorders
- Trial name
- NCT04108273
- Testing
- Organizational Skills Training
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- NYU Langone Health
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
Children between the ages of 6-12 years who are diagnosed with impulsive aggression comorbid with ADHD and have participated in the 810P301 or 810P302 study were invited to participate in this study.
- Trial name
- NCT02691182
- Testing
- SPN-810
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
ADHD, ADD
ADHD Electrophysiological Subtypes and Implications in Transcranial Direct-current Stimulation
In the present study the aim is to examine whether transcranial direct-current stimulation (tDCS) generated excitability changes and induce modifications of functional cortical architecture in Attention Deficit Hyperactivity…
- Trial name
- tdcs&adhd (NCT01649232)
- Testing
- Active tDCS
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Spanish Foundation for Neurometrics Development
ADD, ADHD
Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary Protein
Multicenter, Prospective, randomized, comparative and controlled study about the beneficial effects in behavior and brain connectivity of different dietary patterns in 100 children with ADHD between 7 and 12 years, followed up…
- Trial name
- BrainProtein (NCT01856686)
- Testing
- BP22042013, Low carbohydrate diet
- Where
- United Kingdom
- Volunteers
- 64 people
- Sponsor
- Spanish Foundation for Neurometrics Development
Attention-Deficit/Hyperactivity Disorder (ADHD)
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
This open label, flexible-dose study evaluating the safety and efficacy of SPN-812 administered with psychostimulants in children and adolescents (6 to 17 years of age) with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- ADHD (NCT04786990)
- Testing
- SPN-812
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 96 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Autism Spectrum Disorder, Adhd
A+ Treatment/Feasibility of Adapted ESDM-informed Caregiver Coaching Delivered Remotely for Children With ASD (Autism Spectrum Disorder) and ADHD (Attention Deficit Hyperactivity Disorder)
This study will evaluate the feasibility of adapted ESDM-informed caregiver coaching in children with comorbid ASD and ADHD, who are between 36 and <132 months of age.
- Trial name
- NCT05417607
- Testing
- P-ESDM informed caregiver coaching
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Duke University
ADHD
Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD
Specific Aim 1: As part of a within-subject, two-days, study design, to determine whether acute calcitriol (vs. placebo) pre-treatment is associated with greater amphetamine (Amp)-induced dopamine (DA) release in the caudate…
- Trial name
- NCT03103750
- Testing
- Magnetic Resonance Imaging (MRI), PHNO, calcitriol
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Yale University
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of impulsive aggression in patients with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with standard…
- Trial name
- NCT02618434
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 32 sites in United States
- Volunteers
- 297 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
ADHD, Oppositional Defiant Disorder
Adapting a Web-Based Professional Development for Mexican School Mental Health Providers Delivering Evidence-Based Intervention for ADHD and ODD
Neurodevelopmental disorders of inattention and disruptive behavior, such as Attention-Deficit/ Hyperactivity Disorder (ADHD) and Oppositional Defiant Disorder (ODD), are among the most common youth mental health conditions…
- Trial name
- NCT05425966
- Testing
- CLS-R-FUERTE
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of California, San Francisco
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of Impulsive Aggression (IA) in subjects with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with…
- Trial name
- NCT02618408
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 28 sites in United States
- Volunteers
- 333 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
ADHD
The Effects of ADHD Medication (TEAM) Study
This study evaluates the effects of receiving and then discontinuing methylphenidate (MPH) in children with ADHD. After receiving MPH for 8 weeks, participants will be randomized to either discontinue MPH (and receive placebo) OR…
- Trial name
- TEAM (NCT02293655)
- Testing
- OROS-Methylphenidate (MPH)
- Where
- 2 sites in United States
- Volunteers
- 204 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
ADHD
A Novel fNIRS Neurofeedback Intervention for Enhancement of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)
The proposed study is to test and validate a novel intervention that integrates computerized cognitive training with real-time neuromonitoring and neurofeedback to enhance working memory by probing the individualized neural…
- Trial name
- NCT04002167
- Testing
- Neurofeedback, Cognitive training
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Stanford University
ADHD
Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
To evaluate the efficacy of AMPH ER TAB compared to placebo in adult patients with ADHD aged 18 to 60 years.
- Trial name
- NCT03834766
- Testing
- AMPH ER Tab 5, 10, 15 and 20 mg
- Where
- 3 sites in United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
ADHD
Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication
The purpose of this study is to see if supplementing calories with Pediasure is effective in maintaining height, weight, and BMI percentiles for young children during 2 years of treatment with ADHD medication.
- Trial name
- NCT00561340
- Testing
- Pediasure, Nutritional counseling
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Nebraska
ADHD
Atomoxetine PBPK-PD Clinical Study
The primary aims of this study focus on characterizing the relationship between atomoxetine exposure and clinical outcomes, as assessed by standardized measures.
- Trial name
- NCT03154359
- Testing
- Atomoxetine Hydrochloride
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Children's Mercy Hospital Kansas City
Attention Deficit Hyperactivity Disorder, ADHD
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
This multi-center parallel study is designed to study the efficacy and safety of fixed doses of methylphenidate extended release (ER) capsules of four dose levels compared with a placebo group in pediatric patients with Attention…
- Trial name
- NCT01239030
- Testing
- Methylphenidate Hydrochloride Extended Release Capsules
- Where
- 16 sites in United States
- Volunteers
- 230 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Hyperactivity Disorder, ADHD
Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting
The time course of response following one dose of a new methylphenidate hydrochloride extended release capsule is studied in children 6-12 years in a simulated laboratory classroom setting.
- Trial name
- NCT01269463
- Testing
- Methylphenidate Hydrochloride Extended Release Capsule
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
ADHD, Substance Use Disorders
Integrated Treatment for Adolescents With ADHD
Attention-Deficit/Hyperactivity Disorder (ADHD) exists in 20-50% of the 3 million adolescents annually enrolled in outpatient mental health and substance use treatment.
- Trial name
- CASALEAP IT2A (NCT02420990)
- Testing
- Medication Integration Protocol (MIP), Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- The National Center on Addiction and Substance Abuse at Columbia University